Nancy C Brahm
Affiliation: University of Oklahoma Health Sciences Center
- Commonly prescribed medications and potential false-positive urine drug screensNancy C Brahm
Department of Pharmacy Practice, Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma, 4502 East 41st Street, Tulsa, OK 74135 2512, USA
Am J Health Syst Pharm 67:1344-50. 2010..The implications of potential false-positive urine drug screen (UDS) results for patients receiving commonly prescribed medications were evaluated...
- Case report: increased patient response to intramuscular haloperidol decanoate following a change in needle lengthNancy C Brahm
College of Pharmacy, University of Oklahoma, Tulsa, OK 74135 2512, USA
J Pharm Pract 24:561-3. 2011..Determining the optimum needle length for administration of IM formulations based on individual patient variables has not been extensively reported in patients receiving antipsychotic medication via IM administration...
- Buspirone for autistic disorder in a woman with an intellectual disabilityNancy C Brahm
Department of Pharmacy, College of Pharmacy, University of Oklahoma, Tulsa, OK 74135, USA
Ann Pharmacother 42:131-7. 2008....
- Bedlam Community Health Clinic: a collaborative interdisciplinary health care service for the medically indigentNancy C Brahm
Clinical Pharmacology Services Developmental Disabilities Service Division, College of Pharmacy, University of Oklahoma, Tulsa, OK 74135 2512, USA
J Am Pharm Assoc (2003) 47:398-403. 2007..To describe a collaborative interdisciplinary health care service delivery system for the medically indigent in the Tulsa and northeastern Oklahoma area independent of state or federal funding...
- Quetiapine for acute mania in bipolar disorderNancy C Brahm
Department of Pharmacy Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy UOCP, Tulsa, OK 74135 2512, USA
Am J Health Syst Pharm 64:1045-53. 2007..The efficacy and tolerability of quetiapine in the treatment of acute mania were reviewed...
- Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilitiesNancy C Brahm
Department of Pharmacy Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma UO, Tulsa 74135 2512, USA
Am J Health Syst Pharm 64:827-9. 2007..A case of extrapyramidal symptoms (EPS) following administration of aripiprazole to a man with developmental disabilities who had never received antipsychotic medications and had no history of movement disorders is presented...
- Risperidone for the treatment of fecal smearing in a developmentally disabled adultNancy C Brahm
Department of Pharmacy Practice, University of Oklahom, Tulsa, OK 74135 2512, USA
Am J Health Syst Pharm 64:382-4. 2007..The use of risperidone in decreasing fecal smearing behavior as an expression of nonverbal aggression in a developmentally disabled adult is discussed...
- Clinical pharmacology services: a pharmacist-based consulting service for the developmentally disabledNancy C Brahm
Clinical Pharmacology Services, Developmental Disabilities Services Department, College of Pharmacy, University of Oklahoma, Oklahoma City 73117-1223, USA
Am J Health Syst Pharm 61:487-93. 2004
- Probable quetiapine-mediated prolongation of the QT intervalNasim Aghaienia
Department of Pharmacy Practice, Clinical and Administrative Sciences Tulsa, University of Oklahoma College of Pharmacy, Tulsa, OK 74135, USA
J Pharm Pract 24:506-12. 2011..Quetiapine, an SGA, was a component of the pharmacotherapy regimen. Based on the Naranjo adverse drug reaction probability scale rating criteria, a probable causal association was made...
- Thyroid function alterations following quetiapine initiation in a developmentally disabled adolescentRichard L Dobbs
Ann Pharmacother 38:1541-2. 2004
- Protozoal infections in the developmentally disabled: often overlooked cause of rectal digging and fecal smearingNancy C Brahm
Ann Pharmacother 38:1542. 2004
- Assessment of QTc prolongation following thioridazine withdrawal in a developmentally disabled populationNancy C Brahm
J Clin Psychopharmacol 23:314-5. 2003